Clinica Baviera Asset Resilience Ratio
Clinica Baviera asset resilience ratio. Clinica Baviera (CBAV) has an Asset Resilience Ratio of 14.23% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Clinica Baviera defensive liquidity buffer to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Clinica Baviera (2006–2024)
Asset resilience ratio of Clinica Baviera from 2006 to 2024. This chart shows how Clinica Baviera's Asset Resilience Ratio has changed over time. Read Clinica Baviera debt and liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Clinica Baviera's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Clinica Baviera total assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 0% |
| Short-term Investments | €31.63 Million | 14.23% |
| Total Liquid Assets | €31.63 Million | 14.23% |
Asset Resilience Insights
- Moderate Liquidity: Clinica Baviera has 14.23% of assets in liquid form.
- While adequate for normal operations, this level may limit flexibility during economic stress.
- The company has significant short-term investments, indicating active treasury management.
Clinica Baviera Industry Peers by Asset Resilience Ratio
Compare Clinica Baviera's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Revvity Inc.
NYSE:RVTY |
Diagnostics & Research | 0.00% |
|
Wuhan Thalys Med Tech Co Ltd
SHG:603716 |
Diagnostics & Research | 0.16% |
|
JOONGANG DNM Co.Ltd
KQ:051980 |
Diagnostics & Research | 27.26% |
|
Shanghai Rendu Biotechnology Co. Ltd. A
SHG:688193 |
Diagnostics & Research | 70.50% |
|
Krsnaa Diagnostics Limited
NSE:KRSNAA |
Diagnostics & Research | 9.90% |
|
Sonic Healthcare Ltd
AU:SHL |
Diagnostics & Research | 0.13% |
|
Integral Diagnostics Ltd
AU:IDX |
Diagnostics & Research | 0.03% |
|
Australian Clinical Labs Ltd
AU:ACL |
Diagnostics & Research | 4.11% |
Clinica Baviera Asset Resilience Ratio by Year (2006–2024)
Clinica Baviera asset resilience ratio by year from 2006 to 2024. The table below shows the annual Asset Resilience Ratio data for Clinica Baviera.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 13.42% | €28.44 Million ≈ $33.25 Million |
€211.95 Million ≈ $247.80 Million |
-10.62pp |
| 2023-12-31 | 24.03% | €42.93 Million ≈ $50.19 Million |
€178.64 Million ≈ $208.85 Million |
-1.94pp |
| 2022-12-31 | 25.98% | €38.99 Million ≈ $45.58 Million |
€150.10 Million ≈ $175.49 Million |
+1.86pp |
| 2021-12-31 | 24.12% | €32.27 Million ≈ $37.73 Million |
€133.81 Million ≈ $156.44 Million |
+1.84pp |
| 2020-12-31 | 22.28% | €26.94 Million ≈ $31.49 Million |
€120.92 Million ≈ $141.37 Million |
+19.75pp |
| 2019-12-31 | 2.53% | €2.57 Million ≈ $3.00 Million |
€101.56 Million ≈ $118.74 Million |
-8.03pp |
| 2018-12-31 | 10.56% | €5.89 Million ≈ $6.89 Million |
€55.83 Million ≈ $65.27 Million |
-1.55pp |
| 2017-12-31 | 12.11% | €6.54 Million ≈ $7.64 Million |
€53.99 Million ≈ $63.12 Million |
-4.57pp |
| 2016-12-31 | 16.68% | €7.80 Million ≈ $9.12 Million |
€46.77 Million ≈ $54.68 Million |
-1.70pp |
| 2015-12-31 | 18.38% | €8.52 Million ≈ $9.97 Million |
€46.38 Million ≈ $54.22 Million |
-2.54pp |
| 2014-12-31 | 20.92% | €10.26 Million ≈ $11.99 Million |
€49.04 Million ≈ $57.33 Million |
-0.99pp |
| 2013-12-31 | 21.91% | €10.58 Million ≈ $12.37 Million |
€48.28 Million ≈ $56.44 Million |
+20.59pp |
| 2007-12-31 | 1.32% | €596.82K ≈ $697.75K |
€45.25 Million ≈ $52.90 Million |
-0.03pp |
| 2006-12-31 | 1.35% | €585.35K ≈ $684.34K |
€43.39 Million ≈ $50.73 Million |
-- |
About Clinica Baviera
Clínica Baviera, S.A., a medical company, operates a network of ophthalmology clinics in Spain and Europe. The company is involved in the diagnosis, treatment, and monitoring of various types of visual disorders. Its clinics offers myopia, hyperopia, astigmatism, farsightedness, presbyopia, cataract, retinal, plastic surgery, pediatric ophthalmology, glaucoma, strabismus, cornea, neuro-ophthalmol… Read more